These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22632160)

  • 1. Mechanisms and monitoring of bypassing agent therapy.
    Hoffman M; Dargaud Y
    J Thromb Haemost; 2012 Aug; 10(8):1478-85. PubMed ID: 22632160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
    Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
    J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global Hemostatic Methods to Tailor Treatment With Bypassing Agents in Hemophilia A With Inhibitors- A Single-Center, Pilot Study.
    Chaireti R; Soutari N; Holmström M; Petrini P; Magnusson M; Ranta S; Pruner I; Antovic JP
    Clin Appl Thromb Hemost; 2024; 30():10760296241260053. PubMed ID: 39051565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
    Berntorp E
    Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
    van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
    Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor.
    Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A
    Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring inhibitor patients with the right assays.
    Barrowcliffe TW
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S25-30. PubMed ID: 18544420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic aspects of bypassing agents.
    Negrier C; Dargaud Y; Bordet JC
    Haemophilia; 2006 Dec; 12 Suppl 6():48-52; discussion 52-3. PubMed ID: 17123394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
    Holmberg HL; Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
    Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E;
    Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers.
    Kaya Z; Orhan Ö; Turanlı S; Yenicesu İ; Koçak Ü; Gürsel T
    Blood Coagul Fibrinolysis; 2017 Jul; 28(5):419-422. PubMed ID: 28079537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.
    Tjønnfjord GE; Holme PA
    Vasc Health Risk Manag; 2007; 3(4):527-31. PubMed ID: 17969383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.